How to Prepare Clinical Evaluation Documentation for Overseas Registration of Medical Dressings?

Published: August 29, 2026 15:44 | Updated: August 29, 2026 15:44

To prepare clinical evaluation documentation for overseas registration of medical dressings, manufacturers must first confirm whether the product falls under the target country's medical device regulatory scope, then determine its classification based on intended use, mechanism of action, and risk level, and finally choose the appropriate pathway: exemption, literature-based evaluation, or clinical trial. The documentation should be built as a reusable core technical file with a complete evidence chain, including risk management, biocompatibility, animal testing, clinical literature, or clinical trial data, and must be localized to meet the target market's regulatory expectations.

Executive Summary

Clinical evaluation documentation is a common bottleneck for manufacturers registering medical dressings overseas. You need to confirm whether the product is within the scope of the target country's medical device regulations, then determine classification based on intended use, mechanism of action, and risk level, which dictates whether you can take an exemption, literature-based argumentation, or clinical trial route. A frequent risk is using domestic performance reports as clinical evidence, or directly copying evaluation conclusions from other markets, while ignoring the target country's requirements for equivalence argumentation, literature quality, and clinical data.

When preparing, establish a reusable core technical file and integrate risk management, biocompatibility, animal testing, clinical literature, or clinical trial data into the evidence chain. Also confirm local agent or authorized representative obligations, labeling and instructions for use, post-market surveillance, and update responsibilities. For registrations in GHWP member countries and Southeast Asia, the Middle East, and Latin America, CE or FDA technical documentation can often be reused, but requires localization conversion. Perform a gap analysis early to identify which materials can be used directly and which must be regenerated, reducing deficiencies and timeline delays.

For Chinese medical device manufacturers, a prudent approach is to first perform product classification and documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market materials can be reused. Target market registration typically affects technical files, authorized representatives, importer cooperation, label language, quality system evidence, and subsequent change maintenance. If you only proceed by "submitting these documents," you risk deficiencies or rework in model coverage, evidence-chain consistency, label claims, and certificate control.

AIMEILI recommends planning this issue within the framework of GHWP member countries and multi-country market access strategy, using one set of reusable core technical files to support localization in different markets, rather than recreating documents for each country.

Applicable Scenarios and Core Questions

Medical dressings are a common category in medical device internationalization, including wound dressings, surgical films, waterproof dressings, and functional dressings. Although most dressings are low risk, clinical evaluation documentation is not a matter of "no preparation needed" or "simple translation" for overseas registration.

Common questions include: How exactly should clinical evaluation materials be prepared? First, determine whether the product's intended use falls within the target country's definition of a medical device. For example, a dressing claiming treatment of chronic wounds or containing active ingredients may be classified as a drug or higher-risk device; a plain dressing for covering surgical incisions may be managed at the lowest risk category.

Core questions also include: What is the product classification? Is the registration pathway self-declaration, registration certificate, or pre-market approval? Is clinical evaluation exempt, literature review, or clinical trial? Which existing NMPA, CE, FDA, or ISO 13485 documents can be reused? Who bears local registrant and post-market responsibilities? These determine the scope and workload of documentation.

If you already have registration experience in GHWP member countries (e.g., China, ASEAN countries, Saudi Arabia) or European and U.S. markets, you can adopt a "core file reuse + localization" strategy for other overseas markets, but must perform item-by-item gap analysis to avoid mixing up different countries' requirements.

Registration Decision Logic

Before preparing clinical evaluation materials, regulatory staff should reason through the following logical sequence rather than starting with templates.

First, determine whether the dressing is a medical device in the target country. For example, the U.S. FDA assesses based on intended use and mechanism; ordinary wound dressings are usually medical devices, but claims of releasing silver ions for antibacterial action or participating in wound healing mechanisms may upgrade the classification to Class II or even III.

Second, determine risk classification. Under the EU MDR, most non-invasive wound dressings are Class I, but dressings containing antimicrobial agents, for chronic wounds, or absorbable dressings may be Class IIa or IIb. Southeast Asian countries often follow risk classification but may have different subcategories, directly affecting clinical evaluation requirements.

Third, assess reusability of existing materials. List existing registration certificates, CE technical files, FDA 510(k)s, ISO 13485, and MDSAP certificates. Check whether test reports comply with ISO 10993, performance standards, and whether stability data are usable, as well as whether clinical evaluation reports apply to the target country's population and use environment.

Fourth, confirm the clinical evaluation pathway and evidence requirements. The target country's regulations may allow exemption from clinical evaluation, or may require a systematic literature review, clinical experience data, or local clinical trial data. Confirm early with a local regulatory agent which evidence is typically accepted in technical review.

The overall decision logic is: first define regulatory scope, then classification and pathway, then gap analysis, then determine what new evidence is needed. Do not skip classification and directly prepare a clinical report.

Documentation and Evidence

Clinical evaluation documentation is not an isolated "clinical report" but an evidence chain. You need to organize these materials into a complete technical file.

The most core component is the technical file package, including product description, intended use, working principle, material composition, manufacturing process, sterilization method, shelf life, and packaging validation. The clinical evaluation of a medical dressing should be built on this foundation, demonstrating safety, effectiveness, and acceptable risk in the target population.

Evidence generally includes the following categories:

• Biocompatibility testing according to ISO 10993 series, including cytotoxicity, sensitization, and irritation; for wound-contact dressings, also systemic toxicity, implantation reactions, or degradation products.
• Physical performance testing including adhesion, moisture vapor transmission rate, fluid absorption, barrier performance, and tensile strength; data must support the intended use.
• Preclinical data and literature data. For a literature route, develop a search strategy, select high-quality literature, and assess equivalence to the subject product in materials, structure, indications, and scope of use. For a clinical trial route, design a controlled trial or single-arm target-value study in compliance with GCP.

When applying in GHWP member countries, many accept clinical evaluation summaries from CE or FDA assessments, but require original literature, result interpretation, and comparison with local intended use. Prepare a complete and traceable clinical evaluation report, not just the conclusion page.

Do not overlook clinical information in IFUs and risk management reports. For example, contraindications, warnings, and precautions must be included, and the risk management report should demonstrate that residual risks are acceptable based on clinical literature.

Common Mistakes

• Assuming all medical dressings are exempt from clinical evaluation without additional argumentation for functional products claiming "promoting wound healing" or "antibacterial" effects.
• Directly using clinical evaluation conclusions from other markets without assessing differences in target population, use environment, and equivalent products.
• Treating performance test reports as clinical evidence without any data or literature supporting clinical benefit.
• Ignoring local agent and authorized representative obligations, causing communication failures and inability to submit clinical materials in the local template.
• Overlooking post-market surveillance requirements. Clinical evaluation is not a one-time activity; update it when adverse events or new literature emerge after launch.
• Opaque literature search strategies without specifying databases, time ranges, and screening criteria, making it impossible for reviewers to judge evidence completeness.
• Risk management documents disconnected from clinical evaluation; hazards identified in risk analysis are not addressed in clinical materials.

Enterprise Preparation Checklist

• Define the target market and intended use; verify regulatory boundaries, risk classification, and registration pathway through official websites or consultancies.
• Create a single core technical file directory with version control for easy multi-country reuse.
• Complete ISO 10993 biocompatibility testing and retain raw data and GLP qualification records.
• Complete product performance verification and stability tests; data must correspond exactly to the models and specifications being registered.
• Develop a clinical evaluation plan stating the rationale for choosing exemption, literature, or clinical trial.
• For a literature route, develop a search strategy and retain search strings, literature list, and full texts; for a trial route, engage a qualified CRO and execute per GCP.
• Produce a clinical evaluation report with equivalence argumentation, residual risk, and conclusions.
• Confirm the local agent or authorized representative and define responsibilities in submission, deficiency response, changes, and post-market surveillance.
• Prepare labels and IFU in the target country's language, ensuring inclusion of expected clinical use information.
• Plan post-market clinical follow-up or adverse event reporting mechanisms and update standard operating procedures.

AIMEILI's Regulatory Interpretation and Business Impact

The most common misjudgment is interpreting "clinical exemption" as "no clinical evaluation needed." Even in exempted countries or classifications, you are typically required to demonstrate equivalence to a marketed product or submit literature justifications. Treat clinical evaluation as an evidence chain, not a document to be issued.

The most important early action is not finding a template, but completing regulatory intelligence collection and gap analysis for the target market. Confirm classification and pathway, then spend an afternoon mapping your existing CE technical files, FDA documents, NMPA test reports, and clinical literature into a matrix, judging usability and missing items item by item.

Reusable items include performance tests, biocompatibility reports, ISO 13485 system certificates, and stable final product design data. Items that must be localized include IFUs, labels, packaging regulatory requirements, local language, local agent information, and clinical evaluation reports and risk management documents that may need rewriting according to target country regulations.

Local agents or authorized representatives are critical. Certificate-holding country, change approvals, renewal, and post-market surveillance all depend on them. If agent responsibilities are unclear, overseas registration clinical materials may be delayed due to lack of response to deficiencies or even lead to certificate invalidation.

For multi-country registration, avoid recompiling full file sets for every country. Use one set of core technical files as the base and make "incremental localization" according to target country differences. Before submission, use a gap checklist to avoid deficiencies from format, translation, or evidence-level mismatches, which can significantly shorten registration timelines and consulting costs.

Common Follow-up Questions

Do medical dressings always require a clinical evaluation under the EU MDR?
Not necessarily. Many Class I dressings can be exempted from clinical studies but require literature search and rational justification. Products containing drugs or requiring demonstration of additional clinical benefit, even at low risk, may require more clinical evidence. Determine evidence requirements based on intended use, material properties, and claimed functions.

Can an existing CE clinical evaluation report be used directly for Southeast Asian registration?
No, not directly. Southeast Asian countries accept literature or CE reports as part of the evidence, but typically require re-evaluation of target population, use environment, and local regulatory requirements. You need local agent declarations, and sometimes must reorganize the clinical evaluation summary according to local templates and confirm the report language and format meet requirements.

What is the relationship between clinical evaluation materials and performance test reports?
Performance test reports are part of the clinical evaluation evidence chain, but are not equivalent to clinical evidence. Performance tests answer "does the product meet specifications," while clinical evaluation answers "does the product achieve the expected clinical benefit in the target population with acceptable risk." Both need to be combined and cross-referenced with risk management documents.

Continue Reading

• How to Localize Labels and IFUs for Overseas Registration of Medical Dressings?
• How to Use ISO 13485 Certificates for Overseas Registration of Medical Dressings?
• How to Allocate Authorized Representative Responsibilities for Overseas Registration of Medical Dressings?
• Why Do Registration Timelines for Medical Dressings Get Extended?
• Common Reasons for Deficiency Responses in Overseas Registration of Medical Dressings?
• What Should Be Prepared Before Renewing Overseas Registration of Medical Dressings?

Return to FAQ Center | News | Contact AIMEILI

Content Review and Applicability Boundaries

Author: AIMEILI Regulatory Editorial Team; Professional Review: AIMEILI Medical Device International Registration Project Team.

Source principle: Priority is given to official regulatory agencies, international organizations, standards bodies, and public regulatory materials; industry media and project experience are used only as supplementary judgment.

Applicability: This article is for preliminary understanding, documentation preparation, and project planning. It does not replace official requirements from target country regulators, test results, or legal advice.